Current and future therapeutic targets for pulmonary arterial hypertension

Dustin Fraidenburg, Jason Yuan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fraidenburg, Dustin, Jason Yuan. Current and future targets for pulmonary arterial hypertension. High Alt Med Biol 14:134-143, 2013. - Pulmonary arterial hypertension (PAH) remains a poorly understood disorder with dire consequences. Progression of disease often leads to right heart failure and death without lung transplantation. Limited therapeutic strategies exist for the treatment of PAH and current medical treatment consists of two major categories, supportive care therapeutics and pulmonary vasculature targeted therapy. Supportive care includes anticoagulants and inotropic agents, while pulmonary vasculature targets currently available include endothelin antagonists, phosphodiesterase inhibitors and prostacyclin analogs. While these therapies have shown efficacy in hemodynamic and functional outcomes; halting the progression of disease, reversal, and clinical cure has been elusive. Combination therapy and newer agents may provide innovative insight into the disease process and ultimately change the prognosis of this fatal disease. By utilizing specific targets on the cell membrane, second messengers systems or signaling peptides, novel therapeutic strategies will hopefully emerge. In this review we discuss the currently available therapeutic options and their pulmonary vasculature targets as well as some future therapeutic targets that have promising results in human trials.

Original languageEnglish (US)
Pages (from-to)134-143
Number of pages10
JournalHigh Altitude Medicine and Biology
Volume14
Issue number2
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Pulmonary Hypertension
Therapeutics
Lung
Disease Progression
Phosphodiesterase Inhibitors
Lung Transplantation
Second Messenger Systems
Epoprostenol
Anticoagulants
Heart Failure
Hemodynamics
Cell Membrane
Peptides

Keywords

  • Intracellular enzymes
  • Ion transport
  • Nitric oxide
  • Pulmonary circulation
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Public Health, Environmental and Occupational Health

Cite this

Current and future therapeutic targets for pulmonary arterial hypertension. / Fraidenburg, Dustin; Yuan, Jason.

In: High Altitude Medicine and Biology, Vol. 14, No. 2, 01.06.2013, p. 134-143.

Research output: Contribution to journalArticle

@article{d506b2ad29f94417af79eb4578f5bb43,
title = "Current and future therapeutic targets for pulmonary arterial hypertension",
abstract = "Fraidenburg, Dustin, Jason Yuan. Current and future targets for pulmonary arterial hypertension. High Alt Med Biol 14:134-143, 2013. - Pulmonary arterial hypertension (PAH) remains a poorly understood disorder with dire consequences. Progression of disease often leads to right heart failure and death without lung transplantation. Limited therapeutic strategies exist for the treatment of PAH and current medical treatment consists of two major categories, supportive care therapeutics and pulmonary vasculature targeted therapy. Supportive care includes anticoagulants and inotropic agents, while pulmonary vasculature targets currently available include endothelin antagonists, phosphodiesterase inhibitors and prostacyclin analogs. While these therapies have shown efficacy in hemodynamic and functional outcomes; halting the progression of disease, reversal, and clinical cure has been elusive. Combination therapy and newer agents may provide innovative insight into the disease process and ultimately change the prognosis of this fatal disease. By utilizing specific targets on the cell membrane, second messengers systems or signaling peptides, novel therapeutic strategies will hopefully emerge. In this review we discuss the currently available therapeutic options and their pulmonary vasculature targets as well as some future therapeutic targets that have promising results in human trials.",
keywords = "Intracellular enzymes, Ion transport, Nitric oxide, Pulmonary circulation, Pulmonary hypertension",
author = "Dustin Fraidenburg and Jason Yuan",
year = "2013",
month = "6",
day = "1",
doi = "10.1089/ham.2013.1007",
language = "English (US)",
volume = "14",
pages = "134--143",
journal = "High Altitude Medicine and Biology",
issn = "1527-0297",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Current and future therapeutic targets for pulmonary arterial hypertension

AU - Fraidenburg, Dustin

AU - Yuan, Jason

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Fraidenburg, Dustin, Jason Yuan. Current and future targets for pulmonary arterial hypertension. High Alt Med Biol 14:134-143, 2013. - Pulmonary arterial hypertension (PAH) remains a poorly understood disorder with dire consequences. Progression of disease often leads to right heart failure and death without lung transplantation. Limited therapeutic strategies exist for the treatment of PAH and current medical treatment consists of two major categories, supportive care therapeutics and pulmonary vasculature targeted therapy. Supportive care includes anticoagulants and inotropic agents, while pulmonary vasculature targets currently available include endothelin antagonists, phosphodiesterase inhibitors and prostacyclin analogs. While these therapies have shown efficacy in hemodynamic and functional outcomes; halting the progression of disease, reversal, and clinical cure has been elusive. Combination therapy and newer agents may provide innovative insight into the disease process and ultimately change the prognosis of this fatal disease. By utilizing specific targets on the cell membrane, second messengers systems or signaling peptides, novel therapeutic strategies will hopefully emerge. In this review we discuss the currently available therapeutic options and their pulmonary vasculature targets as well as some future therapeutic targets that have promising results in human trials.

AB - Fraidenburg, Dustin, Jason Yuan. Current and future targets for pulmonary arterial hypertension. High Alt Med Biol 14:134-143, 2013. - Pulmonary arterial hypertension (PAH) remains a poorly understood disorder with dire consequences. Progression of disease often leads to right heart failure and death without lung transplantation. Limited therapeutic strategies exist for the treatment of PAH and current medical treatment consists of two major categories, supportive care therapeutics and pulmonary vasculature targeted therapy. Supportive care includes anticoagulants and inotropic agents, while pulmonary vasculature targets currently available include endothelin antagonists, phosphodiesterase inhibitors and prostacyclin analogs. While these therapies have shown efficacy in hemodynamic and functional outcomes; halting the progression of disease, reversal, and clinical cure has been elusive. Combination therapy and newer agents may provide innovative insight into the disease process and ultimately change the prognosis of this fatal disease. By utilizing specific targets on the cell membrane, second messengers systems or signaling peptides, novel therapeutic strategies will hopefully emerge. In this review we discuss the currently available therapeutic options and their pulmonary vasculature targets as well as some future therapeutic targets that have promising results in human trials.

KW - Intracellular enzymes

KW - Ion transport

KW - Nitric oxide

KW - Pulmonary circulation

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=84879673742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879673742&partnerID=8YFLogxK

U2 - 10.1089/ham.2013.1007

DO - 10.1089/ham.2013.1007

M3 - Article

C2 - 23795733

AN - SCOPUS:84879673742

VL - 14

SP - 134

EP - 143

JO - High Altitude Medicine and Biology

JF - High Altitude Medicine and Biology

SN - 1527-0297

IS - 2

ER -